What is Korio?
Korio operates within the dynamic clinical trial software market, offering a platform designed to streamline complex processes and achieve predictable outcomes within accelerated timeframes. By embedding the expertise of industry subject matter experts directly into its technology, Korio is positioned to disrupt traditional, often manual, workflows that have historically challenged Real-Time Signal Management (RTSM) providers. This innovative approach aims to enhance efficiency and efficacy in clinical research operations.
How much funding has Korio raised?
Korio has raised a total of $6.8M across 1 funding round:
Other Financing Round
$6.8M
Other Financing Round (2023): $6.8M with participation from Boston Millennia Partners and Excelerate Health Ventures
Key Investors in Korio
Boston Millennia Partners
Boston Millennia Partners is a private equity firm specializing in high-growth companies within the healthcare and life sciences industries, bringing extensive experience to support portfolio companies.
Excelerate Health Ventures
Excelerate Health Ventures is a venture capital firm focused on digital healthcare, particularly AI-powered pharmaceutical technology, partnering with visionary founders to advance healthcare solutions.
What's next for Korio?
The substantial enterprise-level funding Korio has garnered suggests a strategic pivot towards scaling its operations and expanding its market reach. This capital injection is likely to fuel further platform development, enhance sales and marketing initiatives, and potentially explore new therapeutic areas or geographical markets. The company's focus on challenging the status quo in clinical trial management indicates a commitment to innovation and a drive to capture a larger share of the market, positioning it for significant future growth.
See full Korio company page
